129 related articles for article (PubMed ID: 10227448)
61. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
[TBL] [Abstract][Full Text] [Related]
62. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
[No Abstract] [Full Text] [Related]
63. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
van der Vijgh WJ; Peters GJ
Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
[TBL] [Abstract][Full Text] [Related]
64. Future directions in gynecologic cancer.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
[TBL] [Abstract][Full Text] [Related]
65. Potential for use of amifostine in cervical cancer.
Small W
Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
[TBL] [Abstract][Full Text] [Related]
66. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose PG
Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
[TBL] [Abstract][Full Text] [Related]
67. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice.
Johnsson A; Olsson C; Anderson H; Cavallin-Ståhl E
Cytometry; 1994 Oct; 17(2):142-50. PubMed ID: 7835164
[TBL] [Abstract][Full Text] [Related]
69. Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutic drugs.
Mazur L; Czyzewska A
Folia Histochem Cytobiol; 2001; 39(2):63-6. PubMed ID: 11374841
[TBL] [Abstract][Full Text] [Related]
70. Rebamipide does not interfere with the antitumor effect of radiotherapy or chemotherapy in human oral tumor-bearing nude mice.
Shibamori M; Sato M; Uematsu N; Nakashima T; Sato A; Yamamura Y; Sasabe H; Umehara K; Sakurai K
J Pharmacol Sci; 2015 Sep; 129(1):18-25. PubMed ID: 26320673
[TBL] [Abstract][Full Text] [Related]
71. Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats.
Caloglu M; Yurut-Caloglu V; Durmus-Altun G; Oz-Puyan F; Ustun F; Cosar-Alas R; Saynak M; Parlar S; Turan FN; Uzal C
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):523-30. PubMed ID: 19673935
[TBL] [Abstract][Full Text] [Related]
72. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
73. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
74. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
Zhang J; Wang X; Lu H
Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
[TBL] [Abstract][Full Text] [Related]
75. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
[TBL] [Abstract][Full Text] [Related]
76. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Kudoh S; Takada M; Masuda N; Nakagawa K; Itoh K; Kusunoki Y; Negoro S; Matsui K; Takifuji N; Morino H
Jpn J Cancer Res; 1993 Feb; 84(2):203-7. PubMed ID: 8385085
[TBL] [Abstract][Full Text] [Related]
77. Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma.
Kikuchi Y; Oomori K; Kizawa I; Hirata J; Kita T; Miyauchi M; Kato K
Cancer Res; 1987 Dec; 47(24 Pt 1):6459-61. PubMed ID: 3677086
[TBL] [Abstract][Full Text] [Related]
78. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
79. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
80. Protective effect of royal jelly and green tea extracts effect against cisplatin-induced nephrotoxicity in mice: a comparative study.
Yapar K; Cavuşoğlu K; Oruç E; Yalçin E
J Med Food; 2009 Oct; 12(5):1136-42. PubMed ID: 19857080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
